PharmAbcine: PharmAbcine gets Australian nod for p1 clinical trial of Keytruda-combined cancer drug

PharmAbcine received approval from the Australian Human Research Ethics Committees (HRECs) last Friday to conduct a phase 1a/b clinical trial of PMC-309.PMC-309 is a VISTA-targeted immuno-oncology agent for patients with advanced or metastatic solid tumors.According to PharmAbcine, PMC-309 is an IgG